Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma

Journal of Gastroenterology

Volumn 52, Issue 4, 2017, Pages 512-519

  Ikeda, Kenji ^a   Kudo, Masatoshi ^b   Kawazoe, Seiji ^c   Osaki, Yukio ^d   Ikeda, Masafumi ^e   Okusaka, Takuji ^f   Tamai, Toshiyuki ^g   Suzuki, Takuya ^g   Hisai, Takashi ^g   Hayato, Seiichi ^g   Okita, Kiwamu ^h   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Saga Ken Medical Centre Koseikan   (Japan)

^d OSAKA RED CROSS HOSPITAL   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^f NATIONAL CANCER CENTER HOSPITAL   (Japan)

^g EISAI CO LTD   (Japan)

^h Shunan Memorial Hospital   (Japan)

Author keywords

E7080; Hepatocellular carcinoma; Lenvatinib; Tyrosine kinase inhibitor; Vascular endothelial growth factor inhibitor

Indexed keywords

LENVATINIB; THYROTROPIN; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; PROTEIN KINASE INHIBITOR; QUINOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACKACHE; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG WITHDRAWAL; DYSPHONIA; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INSOMNIA; LIVER CELL CARCINOMA; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PATIENT SAFETY; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEINURIA; RASH; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; STOMATITIS; THROMBOCYTOPENIA; THYROTROPIN BLOOD LEVEL; TREATMENT RESPONSE; VOMITING; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISEASE COURSE; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; QUINOLINES; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84990853616     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-016-1263-4     Document Type: Article

References (28)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.
2. Poon RT, Ho JW, Tong CS, Lau C, Ng IO, Fan ST. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg. 2004;91:1354–60.
3. Bertino G, Demma S, Ardiri A, et al. Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. Biomed Res Int. 2014;2014:203693.
4. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.
5. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.
6. Llovet JM, Hernandez-Gea V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res. 2014;20:2072–9.
7. Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013;31:4067–75.
8. Ogasawara S, Kanai F, Obi S, et al. Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma. Hepatol Int. 2011;5:850–6.
9. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008;14:5459–65.
10. Tohyama O, Matsui J, Kodama K, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014:638747.
11. Yamamoto Y, Matsui J, Matsushima T, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014;6:18.
12. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621–30.
13. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698–711.
14. Ikeda M, Okusaka T, Mitsunaga S, et al. Safety and pharmacokinetics of lenvatinib in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2016;22:1385-94.
15. Boss DS, Glen H, Beijnen JH, et al. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer. 2012;106:1598–604.
16. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
17. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60.
18. Edeline J, Boucher E, Rolland Y, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer. 2012;118:147–56.
19. Mano Y, Kusano K. A validated LC-MS/MS method of total and unbound lenvatinib quantification in human serum for protein binding studies by equilibrium dialysis. J Pharm Biomed Anal. 2015;114:82–7.
20. Sherman M, Mazzaferro V, Amadori D, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and vascular invasion or extrahepatic spread: a subanalysis from the SHARP trial [abstract]. J Clin Oncol. 26:15S. 2008. (abstr 4584).
21. Johnson PJ, Qin S, Park JW, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013;31:3517–24.
22. Cainap C, Qin S, Huang WT, et al. Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol. 2015;33:172–9.
23. Li P, Wang SS, Liu H, et al. Elevated serum alpha fetoprotein levels promote pathological progression of hepatocellular carcinoma. World J Gastroenterol. 2011;17:4563–71.
24. Takeda H, Nishikawa H, Osaki Y, et al. Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan. Liver Int. 2015;35:1581–9.
25. Wright G, Chattree A, Jalan R. Management of hepatic encephalopathy. Int J Hepatol. 2011;2011:841407.
26. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer. 2007;7:475–85.
27. Shumaker R, Aluri J, Fan J, Martinez G, Pentikis H, Ren M. Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration. J Clin Pharmacol. 2015;55:317–27.
28. Finn RS, Cheng AL, Ikeda K, et al. A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) verus sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma [abstract]. J Clin Oncol.32:5s. 2014. (abstr TPS4153).